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Background: The activation of blood coagulation could contribute to the failure of in-vitro fertilization (IVF) techniques.
The aim of this study was to assess the predictive value of D-dimer levels for pregnancy outcome in women
undergoing IVF.
Findings: A prospective study was performed in 105 women undergoing IVF. D-dimer was measured before
and one week after the administration of recombinant human chorionic gonadotropin (r-hCG). The primary
outcome of the study was clinical pregnancy. The mean age was 36 years (range 26 to 43 years). The main
indications for IVF were infertility due to a tubaric (n = 21, 20%) or male factor (n = 37, 35%) and idiopathic infertility
(n = 30, 29%) which altogether accounted for 84% of the total. Clinical pregnancy was achieved by 40/105 (38%)
women of whom 32 (80%) delivered a live child. On the day of r-hCG administration, D-dimer concentrations
were significantly higher in patients not achieving a clinical pregnancy (141 ng/dL vs. 115 ng/dL, p = 0.035)
which remained statistically significant after correction for age and indications for IVF in multivariable analysis
(p = 0.032). One week after r-hCG, the levels of D-dimer were significantly increased both in women with and
without a clinical pregnancy with no differences between the groups (748 ng/dL vs. 767 ng/dL, p = 0.88).
Conclusions: D-dimer concentrations seem to predict a higher risk of pregnancy failure in women undergoing
IVF. If confirmed in future prospective studies, D-dimer could help identifying a group of patients who could benefit
from prophylaxis to increase the pregnancy success rate.
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The average pregnancy rate after in-vitro fertilization
(IVF) remains as low as 30% [1]. One of the possible
mechanisms behind the high failure rate is the unsuc-
cessful implantation or placentation due to hypercoagula-
bility causing thrombosis of maternal vessels with reduced
perfusion of the intervillous space and placentation failure
[2]. A number of studies evaluated the causal relationship
between states of hypercoagulability and outcomes of IVF
reporting conflicting findings, as summarised in a recent
systematic review of the literature [3].
The hormonal milieu resulting from the use of contra-
ceptive pills or hormone replacement therapy has been
clearly associated with hypercoagulability [4,5]. By contrast,* Correspondence: tiboni@unich.it
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rameters of supra-physiological oestrogen levels as seen
during IVF [6]. Although the interpretation of the data re-
mains difficult due to the relatively small size of the stud-
ies and the heterogeneity of IVF protocols, the available
evidence suggests that ovarian stimulation during IVF is
associated with increased concentrations of coagulation
factors and impairment of endogenous anticoagulants. All
these haemostatic changes seem amplified in cases of exces-
sive ovarian response as it occurs in the ovarian hyperstim-
ulation syndrome (OHSS) [7]. Interestingly, preliminary
observations suggested that haemostatic markers such as
D-dimer are associated with an unfavourable pregnancy
outcome in women with OHSS [7].
The aim of this prospective study was to evaluate
the association between plasma D-dimer levels and IVF
outcome.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Patients
Women attending the Assisted Reproduction Unit of
the Ortona General Hospital and undergoing IVF from
January 2011 to December 2012 were eligible for the
study. Indications for IVF treatment included anovulation,
endometriosis, tubal factor, male factor, mixed factor and
unexplained infertility. Exclusion criteria were the ongoing
use of anticoagulants at prophylactic or therapeutic doses
or unwillingness to provide consent for the participation
in the study. High responders that were coasted to prevent
OHSS were also excluded. The study was conducted in
compliance with the Helsinki Declaration and informed
consent was obtained from all participants.
Ovarian stimulation protocol
Gonadotropin Releasing Hormone (GnRH) agonist or an-
tagonist were used to prevent premature luteinizing hor-
mone (LH) surges. Ovarian stimulation was performed
using daily subcutaneous injections of recombinant follicle-
stimulating hormone (r-FSH; Puregon, Merk Sharpe and
Dome, Germany; Gonal F, Merk Serono, Switzerland) at
doses ranging from 75 IU to 450 IU depending on the
woman’s age, the antral follicle count (AFC), and the basal
(day 3) FSH circulating level. Controlled ovarian stimula-
tion was started on day 3 of full menstrual flow if pituitary
suppression was complete, as shown by absence of ovarian
cysts, serum estradiol < 50 pg/ml and endometrial thick-
ness < 3 mm. Gonadotropin dosage was adjusted accord-
ing to the individual response. Recombinant human
chorionic gonadotropin (r-hCG; Ovitrelle, Merk-Serono,
Switzerland ) was administered when at least three leading
follicles reached 18 mm. Oocyte pick-up was scheduled
36 hours after r-hCG injection. All the collected oocytes
were denuded and their nuclear maturation stage deter-
mined. All the in-vitro fertilizations were performed by
intracytoplasmic sperm injection (ICSI). Embryo transfer
was performed 72–76 hours after ovum pick-up. A luteal
phase support of 600 mg/day micronized intravaginal pro-
gesterone (Progefik, Effikitalia, Italy) was started the day
after oocyte retrieval and maintained until a pregnancy
test was performed, or until the seventh week’s gestation if
the patient tested positive. Pregnancy test was performed
by dosing serum βhCG levels, 14 days after embryo trans-
fer. Clinical pregnancy was defined as the presence of a
gestational sac with accompanying fetal heart beat as ob-
served by ultrasound at seven weeks gestation.
Blood collection
Venous blood was collected from an antecubital vein
without venous stasis using a 19-gauge butterfly needle.
Blood withdrawal was planned 48 hours before the ad-
ministration of r-hCG (maximal estrogens concentra-
tion) and between eight to ten days afterwards. Bloodsamples for D-dimer test were collected into tubes contain-
ing a mixture of sodium citrate, centrifuged for 15 minutes
at 3,000 × g, and stored at −80°C until further analysis.
D-dimer concentrations were measured by a latex
quantitative assay (D-dimer Plus assay, Dade Behring,
Marburg, Germany) with a cut-off value of 200 ng/mL
for an abnormal test result according to the manufac-
turer indications.
Statistical analysis
Information on baseline characteristics, risk factors, and
treatments were analyzed by means of descriptive statis-
tics. Variables with a non-parametric distribution were
presented as medians (range) and those with a paramet-
ric distribution as means (± standard deviation). Differ-
ences between women achieving a clinical pregnancy
and women with a pregnancy failure were tested with
the Mann–Whitney U test or the T-test, as appropriate.
Variables with a statistical significance corresponding to
a p < 0.15 in univariate analysis were assessed in multi-
variate logistic regression analysis. D-dimer levels were
analysed as a continuous variable and according to the
cut-off of the assay for positivity (200 ng/dL) comparing
values above and below the cut-off. All statistical ana-
lyses were performed using SPSS software (version 20;
SPSS Inc, Chicago, Illinois).
Results
The clinical characteristics of the study population are
shown in Table 1. The mean age was 36 years (26 to
43 years). In over two thirds of the cases infertility was idio-
pathic or the consequence of a male or tubal factor. Overall,
5 (4.8%) of 105 women achieved a biochemical pregnancy,
and 40 (38%) obtained a clinical pregnancy of whom 32
(80%) delivered a live child which was pre-term (before
37 weeks gestation) in 23 (72%) (Table 2). Twin pregnancy
occurred in 9/40 (22%) women, and in one case pregnancy
was complicated by intra uterine growth restriction. Seven
women aborted before the 12th week gestation (17%) and
one experienced an extra uterine pregnancy. There were
no thromboembolic complications during the study and
pharmacological thromboprophylaxis was not adminis-
tered to any patient during IVF.
Women achieving clinical pregnancy were similar for
age, vascular risk factors, indication for IVF, and IVF pro-
cedures to women who had a pregnancy failure (Tables 1
and 2).
D-dimer levels
Circulating levels of D-dimer measured just before the
administration of r-hCG were significantly higher in
women with a pregnancy failure (141 ng/mL, range 42
to 499 ng/mL) compared to those achieving a clinical
pregnancy (115 ng/mL, range 16 to 215 ng/mL; p = 0.035)
Table 1 Clinical and demographic characteristics of the
study population
Characteristic Viable pregnancy P value
Yes (n = 40) No (n = 65)
Age, years 36 (27–43) 36 (26–43) 0.97
BMI, kg/m2 22 (17–39) 21 (16–39) 0.26
Smoking 7 (17) 11 (17) 0.94
Arterial hypertension 0 1 (1) 0.43
Diabetes 0 0 -
History of cardio-cerebrovascular
disease




Indication for IVF 0.26
Male factor 11 (27) 26 (40)
Tubaric 8 (20) 13 (20)
Idiopathic 15 (37) 15 (23)
Ovulatory 5 (12) 4 (6)
Endometriosis 1 (2) 5 (8)
Recurrent miscarriage 0 2 (3)
Previous pregnancy 8 (20) 9 (14) 0.41
Previous miscarriage 0.62
No 37 (92) 57 (88)
1 1 (2.5) 5 (8)
2 1 (2.5) 2 (3)
3 1 (2.5) 1 (1)
≥ 3 0 0







1 1 (2) 2 (3)
2 4 (10) 7 (11)
3 34 (85) 55 (85)








Basal FSH mUI/ml 6.6 (4.2-12.3) 7.4 (2.1-18.3) 0.31
Legend: Continuous variables are presented as means ± standard deviations
(SD), or as medians with their range, in case of skewed distributions. Data are
presented as absolute numbers (%) for ordinal variables. BMI body-mass index;
FSH = ; IU international units; IVF in-vitro fertilization; r-hCG recombinant
human chorionic gonadotropin.
Table 2 Outcomes of the IVF procedure
GnRH antagonist protocol, n (%) 27/105 (26)
Retrieved oocytes, n (range) 7 (2–25)
Metaphase II oocytes, n (range) 5 (1–18)
Biochemical pregnancy only, n (%) 5/105 (5)
Implantation rate, % (range) 19% (0 to 100%)
Live birth rate, n (%) 32/105 (30)
Clinical pregnancy, n (%) 40/105 (38)
Twin pregnancy, n (%) 9/40 (22)
Triplets, n (%) -
Ectopic pregnancy, n (%) 1/40 (2)
Pregnancy loss, n (%) 7/40 (17)
Legend: GnRH Gonadotropin Releasing Hormone.
Figure 1 D-dimer levels in women with and without a clinical
pregnancy. White bars: D-dimer in women without clinical pregnancy;
grey bars: D-dimer in women with clinical pregnancy. r-hCG =
Recombinant human chorionic gonadotropin.
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after correction for age and indications for IVF in multi-
variable analysis (p = 0.032). D-dimer levels above theassay cut-off of positivity (200 ng/mL) were also associated
with a worse outcome (p = 0.042).
One week after the administration of r-hCG, D-dimer
values were significantly increased compared to the levels
before r-hCG with no significant differences between
women with and without a clinical pregnancy (748 ng/mL
[range 161 to 1057 ng/mL] vs. 767 ng/mL [range 52 to
3140 ng/mL], p = 0.88).
Discussion
In the current study we found that D-dimer levels mea-
sured before the administration of r-hCG were predict-
ive of an unfavourable pregnancy outcome.
Relatively few studies with a low number of partici-
pants and with several methodological drawbacks ex-
plored the changes in haemostatic parameters during
IVF [7-10]. In a small case–control study, Rogolino and
colleagues found significantly higher concentrations of
D-dimer, tissue factor, and protrombin fragments 1 + 2
in women hospitalised for OHSS relative to healthy
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ences between controls and women undergoing IVF with-
out OHSS. In another series of 33 women, Curvers and
colleagues found only modest changes in the plasma
levels of natural anticoagulant proteins despite the
considerable variation in hormonal concentrations dur-
ing the IVF cycle [10].
The D-dimer test is a widely available test which is rou-
tinely used in the diagnostic work-up of venous thrombo-
embolic events [11]. In patients at high risk of thrombotic
complications, D-dimer measurement helps stratifying
the risk of first or subsequent thrombosis and has the
potential to identify subgroups warranting primary prophy-
laxis or prolonged anticoagulation [12,13]. To our know-
ledge, this is the first study to show a negative prognostic
value of D-dimer in women undergoing IVF. These re-
sults extend previous observations which suggested an
association between an unfavourable pregnancy outcome
and D-dimer levels in women undergoing IVF and devel-
oping OHSS [7]. The present findings need to be consid-
ered cautiously due to the size of the included population
which did not allow to explore the relationship of D-
dimer with live birth rate or identify the D-dimer cut-off
that best predict pregnancy success or failure. Future lar-
ger studies are warranted to clarify these issues.
D-dimer levels increased considerably one week after
the trigger r-hCG injection, in agreement with earlier
observations by Biron and colleagues who reported a
significant activation of various haemostatic parameters
following r-hCG [14]. While the mechanisms behind
the activation of blood coagulation following r-hCG
remain unclear, the changes in D-dimer concentra-
tions observed in the current study were apparently not
related to the final pregnancy outcome. Measurement of
D-dimer at later time points after r-hCG could clarify
whether these increased D-dimer levels persist long after
the r-hCG stimulation or return to pre-stimulation values
after a plateau phase. In this latter case, the high concen-
trations of D-dimer would reflect a transitory peak in
blood coagulation activation not sufficiently prolonged to
cause thrombosis of the maternal vessels.
In conclusion, we found that D-dimer concentrations
seem to predict a higher risk of pregnancy failure in
women undergoing IVF. If confirmed in future prospect-
ive studies, D-dimer could help identifying a group of
patients who could benefit from prophylaxis to increase
the pregnancy success rate.
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